Neoadjuvant therapy gains FDA approval in non-small cell lung cancer.
rct · Level I
Where this comes from
- Record sourced from PubMed, PMID 35858590.
- Also identified by DOI 10.1016/j.xcrm.2022.100691 and PMC identifier 9381414.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Forde et al.<sup>1</sup> reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms